Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page
- Check5 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5 on the page metadata. This indicates an internal update to the page’s version, with no visible changes to the study details or user-facing content.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision: v3.6.4 has been added, replacing the previous v3.6.3 revision. This indicates a small update to the page's documentation or metadata rather than substantive content changes.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe revision label was updated from v3.6.2 to v3.6.3, signaling a version update for the page.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, indicating a newer build of the page. This update affects only the versioning metadata displayed on the page and does not modify the study content.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page adds a recruitment status line ('No longer looking for participants') and new help sections (How to Read a Study Record, Common Questions, How to Join a Study), and it also updates the Intervention/Treatment header formatting along with the revision label to v3.6.0, reflecting a mix of usability improvements and cosmetic/version changes.SummaryDifference0.4%

- Check69 days agoChange DetectedThe page's revision tag was updated to reflect a newer internal version. This indicates a small update to the page rather than a change to study details or user-facing content.SummaryDifference0.0%

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.